Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders. This often ...

The FDA has granted Orphan Drug designation to ersodetug (RZ358) for the treatment of hypoglycemia due to tumor hyperinsulinism.

In a report released on December 3, Julian Harrison from BTIG maintained a Buy rating on Rezolute (RZLT – Research Report), with a price target ...

AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration ...

UI Health has announced it is the exclusive provider of an FDA-approved therapy for the most critical form of Type 1 diabetes ...

Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs ...

A new therapy for brittle type 1 diabetes, the only treatment currently approved by the U.S. Food and Drug Administration, is ...

Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs to ...

We also encourage providers to routinely question their patients about severe hypoglycemia, educate them about hypoglycemia prevention and treatment strategies, and consider modifying treatment ...

Instead, they can get severe hypoglycemia without warning ... have the disease until they develop symptoms of DKA and seek treatment. Some common causes of DKA include: Problems with insulin.

This report details a third cause of cerebral symptoms after hemodialysis – that of hypoglycemia. Case Report E.S. (W.C.G.H. 332485), a 33-year-old man with renal failure secondary to chronic ...